Medicare’s expanded joint replacement bundle is set to reset hospital economics
Medicare’s Comprehensive Care for Joint Replacement Expanded model, or CJR-X, will make 2,217 acute care hospitals financially accountable for hip, knee and ankle replacements in Original Medicare starting Jan. 1, 2028. The model was finalized July 31 in CMS’ fiscal 2027 inpatient payment rule, and the episode window runs from surgery through 90 days after discharge, including both inpatient and hospital outpatient procedures. For hospitals built around fee-for-service volume, the shift is blunt: the total cost of an episode, not the individual service line, becomes the financial unit that matters.
CMS estimates the model will save Medicare $736 million across five performance years. That projection places CJR-X squarely in the same policy lineage as earlier episode-based payment efforts, but with a broader footprint and a more forceful reach into orthopedic care. The original CJR model, which covered about 800 hospitals from 2016 to 2024, generated an estimated $112.7 million in net savings from 2021 to 2023. CJR-X takes that experience and extends it into a larger mandatory structure, widening the number of hospitals forced to manage post-acute spending, implant costs, length of stay, readmissions and discharge patterns as one financial package.
The pressure point is not abstract. Christian Pean, MD, assistant professor of orthopedic surgery and executive director for AI and IT innovation at Duke University School of Medicine in Durham, N.C., described the model as a coming shock for systems that have not already organized around it. Duke has assembled about 40 stakeholders who meet every week, a pace that reflects how much operational work is required before the first claims ever hit the system. In his view, the policy is less a gentle incentive than a structural correction.
Hospitals that still treat bundled payment preparation as a finance-office exercise are exposed to avoidable losses. Episode accountability for joint replacement demands direct coordination among orthopedic surgeons, perioperative teams, inpatient medicine, case management, analytics staff, anesthesia, rehabilitation partners and administrators who can redesign how a patient moves from consult to discharge.
Outpatient joints, ASCs and the fight over who owns the episode
Duke’s preparation strategy is organized around a few practical questions: what each episode actually costs, which patients can safely move through same-day pathways, how digital wraparound services can reduce avoidable utilization, and how to document the complexity of cases that still require an inpatient stay. Those are not separate tasks; they are the financial mechanics of bundled care. A hospital that cannot distinguish routine arthroplasty from a complicated admission will struggle to defend its margins under a model built to compare expected and actual spending.
The ASC strategy may prove just as consequential. Pean expects CJR-X to push more total joints into outpatient settings, and other systems are already moving in that direction. Endeavor Health’s Skokie, Ill., Hospital is exploring a value-based enterprise to better align with surgeons, and its president described outpatient total joints as “the gold standard” because even a one-night admission can erode the cost target. In bundle economics, a short inpatient stay is not a small operational variation; it is often the difference between meeting target spending and missing it.
Hospitals also face a thorny attribution problem. CJR-X places the financial risk on hospitals, but ASCs may still feel the downstream effects through gainsharing arrangements, especially when hospitals share savings with ambulatory partners. CMS has not said how episodes will be attributed to freestanding, physician-owned ASCs with no ownership connection to a participating hospital. That uncertainty leaves a major operational gap in a market where surgeons are already shifting more procedures to lower-cost sites of care.
The policy architecture is layered. CJR-X builds on TEAM, the Transforming Episode Accountability Model, another mandatory CMS bundle that began Jan. 1, 2026, for 716 hospitals. TEAM covers lower extremity joint replacement and four other surgical episodes, each lasting 30 days. Hospitals participating in TEAM are exempt from CJR-X until TEAM ends on Dec. 31, 2030. Even with that exemption, the direction of travel is unmistakable: Medicare is steadily expanding mandatory episode-based payment, and orthopedics sits at the center of the effort.
The design has a clear biological and economic logic. Joint replacement care is a predictable, high-volume service line with measurable downstream utilization, which makes it well suited for bundled payment control. A well-run episode reduces unnecessary overnight stays, limits avoidable complications, shortens recovery-related spending and channels appropriate patients toward outpatient surgery. A poorly coordinated one does the opposite, allowing post-op variation to turn into a direct financial penalty.
Dr. Pean expects the model’s reach to extend beyond hospitals. He said bundles are likely to reach ASCs directly within three to five years.
“They’re coming to the ASCs,” he said.
He also expects new alliances that would have sounded improbable a few years ago, including joint ventures between payers and hospitals. He described those organizations as “the enemies usually,” a blunt way of capturing how payment reform is forcing former competitors to work from the same cost ledger.
Physician alignment sits at the center of that change. Pean said hospitals have done “a pretty poor job” of aligning with physicians, while ASCs have often handled that relationship more effectively. In a mandatory bundle, that gap is not cosmetic. Surgeon preferences influence implant selection, discharge timing, rehab use and the threshold for same-day surgery, all of which shape episode expense. Systems that cannot bring physicians into the economic redesign may find themselves paying for care they do not control.
The coming test is operational as much as financial. By the time CJR-X begins in 2028, hospitals will need reliable cost accounting, a defined outpatient joint strategy, documentation that captures case complexity and a tighter relationship with surgeons and ambulatory partners. Medicare has already set the episode, the accountability window and the number of hospitals in scope. What remains unsettled is how many systems will have reworked their orthopedic pathways before the first performance year begins, and how many will be learning the rules after the penalties arrive.